<?xml version="1.0" encoding="UTF-8"?><ns2:project xmlns:ns1="http://gtr.rcuk.ac.uk/gtr/api" xmlns:ns2="http://gtr.rcuk.ac.uk/gtr/api/project" xmlns:ns3="http://gtr.rcuk.ac.uk/gtr/api/fund" xmlns:ns4="http://gtr.rcuk.ac.uk/gtr/api/person" xmlns:ns5="http://gtr.rcuk.ac.uk/gtr/api/project/outcome" xmlns:ns6="http://gtr.rcuk.ac.uk/gtr/api/organisation" ns1:created="2026-06-03T15:52:43Z" ns1:href="http://gtr.ukri.org/gtr/api/projects/5B205A51-80EC-4A30-99FD-12345ED79E9A" ns1:id="5B205A51-80EC-4A30-99FD-12345ED79E9A"><ns1:links><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/persons/1CD9493D-0881-4700-8EBE-27C91EE4E9C0" ns1:rel="PM_PER"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/0F2F14E7-A160-4734-88E6-B2FD81340361" ns1:rel="LEAD_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/0F2F14E7-A160-4734-88E6-B2FD81340361" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:end="2012-11-30T00:00:00Z" ns1:href="http://gtr.ukri.org/gtr/api/funds/A94AFBC9-8981-4E0A-A9B5-8CBD5D36F4BE" ns1:rel="FUND" ns1:start="2012-07-31T23:00:00Z"/></ns1:links><ns2:identifiers><ns2:identifier ns2:type="RCUK">130836</ns2:identifier></ns2:identifiers><ns2:title>Development of a rapid prototype for the feasibility assessment of obstructive sleep apnoea</ns2:title><ns2:status>Closed</ns2:status><ns2:grantCategory>Feasibility Studies</ns2:grantCategory><ns2:leadFunder>Innovate UK</ns2:leadFunder><ns2:abstractText>Anaxsys Ltd is developing an inexpensive and easy to use device for the diagnosis of Obstructive Sleep Apnoea (OSA) which is a condition that is growing in incidence and studies have shown that up to 45% of middle aged men may suffer to some degree. OSA is often characterised by heavy snoring, feeling tired during the day and can cause depression and in severe cases can affect an individual’s ability to work effectively and to drive safely. Once diagnosed OSA can be easily and effectively treated however the lack of an inexpensive and easy to use home diagnostic tool has resulted in a diagnosis rate of only approximately 10% of sufferers in the developed world.</ns2:abstractText></ns2:project>